Brain metastases are quite frequent in patients with ALK-translocated non-small cell lung cancer (NSCLC): they are often not amenable to surgical resection and are generally treated with radiotherapy (RT). This however causes severe late toxic side effects that may become invalidating considering the relatively long survival provided by recent medical treatment with target therapies. Several clinical trials have demonstrated that ALK-inhibitors (crizotinib, alectinib, brigatinib) show excellent activity also against brain metastases. It is therefore reasonable, in asymptomatic patients, to start treatment with specific inhibitors: RT will be used at the time of tumor progression or when symptoms appear. This sequence provides the best quality of life for patients.
Treatment of brain metastases in ALK-positive non-small cell lung cancer / Ceddia, Serena; Codacci-Pisanelli, Giovanni. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 165:(2021), p. 1. [10.1016/j.critrevonc.2021.103400]
Treatment of brain metastases in ALK-positive non-small cell lung cancer
Ceddia, Serena
Primo
Writing – Original Draft Preparation
;Codacci-Pisanelli, Giovanni
Ultimo
Writing – Original Draft Preparation
2021
Abstract
Brain metastases are quite frequent in patients with ALK-translocated non-small cell lung cancer (NSCLC): they are often not amenable to surgical resection and are generally treated with radiotherapy (RT). This however causes severe late toxic side effects that may become invalidating considering the relatively long survival provided by recent medical treatment with target therapies. Several clinical trials have demonstrated that ALK-inhibitors (crizotinib, alectinib, brigatinib) show excellent activity also against brain metastases. It is therefore reasonable, in asymptomatic patients, to start treatment with specific inhibitors: RT will be used at the time of tumor progression or when symptoms appear. This sequence provides the best quality of life for patients.File | Dimensione | Formato | |
---|---|---|---|
Ceddia_Treatment_brain_metastases_2021.pdf
solo gestori archivio
Note: https://www.sciencedirect.com/science/article/pii/S1040842821001888?via=ihub
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
552.67 kB
Formato
Adobe PDF
|
552.67 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.